PathAI Acquired by Roche | Healthcare M&A Deal

Roche has acquired PathAI, a diagnostics imaging business in Massachusetts, for up to $1.05 billion. Roche acquisitions will bring PathAI’s digital pathology platform to automate tissue slide imaging and support AI-assisted analysis of patient samples for cancer diagnosis. Based in Boston, PathAI develops AI models for diagnostic workflows and also provides tools for clinical trial support and translational research. This strategic acquisition is structured as a merger acquisition with $750 million paid upfront and up to $300 million in milestone payments, expected to close in the second half of 2026 subject to antitrust and regulatory approvals. Roche plans to integrate PathAI’s digital pathology tools with its oncology diagnosis platforms and companion diagnostic algorithms.